Effectiveness and Safety of Firmagon in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Nov 2015
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms FAST-AR
- Sponsors Ferring Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 29 Oct 2015 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018 as reported by ClinicalTrials.gov record.
- 29 Oct 2015 Planned primary completion date changed from 1 Jun 2018 to 1 Aug 2018 as reported by ClinicalTrials.gov record.